Techno Trends
Teva’s unique Talent Management program facilitates early detection of employees with high potential
Leadership Development Our vision is to consistently develop individuals and improve overall performance to support Teva in attaining its strategy of business growth. Career development at Teva is therefore considered an essential element and perceived as a...
Techno Trends
Mene Pangalos elected to the Fellowship of the Academy of Medical Sciences
IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK Each year the Academy of Medical Sciences elect a small number of UK scientists to their Fellowship in recognition...
Techno Trends
AstraZeneca and the University of Cambridge announce new joint PhD and clinical research scholarships
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. The programmes reflect the...
Techno Trends
Ireland’s Shire to acquire NPS Pharmaceuticals for $5.2bn
Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn. As part of the deal, Shire will acquire NPS Pharma's outstanding shares for $46 per share in cash. The transaction was...
Techno Trends
Biogen to acquire British biopharmaceutical firm Convergence
US-based Biogen Idec is set to acquire British clinical-stage biopharmaceutical company, Convergence Pharmaceuticals. As part of the deal, Convergence shareholders will receive an upfront payment of $200m from Biogen. The shareholders are also eligible to receive...
Techno Trends
Insourcing IV Sterile Compounding
Determined to cement access to reliable and safe sources for crucial IV drug admixtures, a growing number of hospitals are bringing production of compounded sterile products (CSPs) in-house and turning their backs on external compounding pharmacies. Such far-reaching decisions...
Techno Trends
Novartis buys GSK’s cancer drugs for $16 bn in three-part deal
Global pharma major Novartis will acquire GlaxoSmithKline Plc's (GSK) cancer drugs portfolio for $16 billion and sell its vaccines business in return for $7.1 billion, apart from forming a joint venture for the consumer healthcare business in a three-part...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read